Article
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
Genes & development - 1 Mar 2015
Guillemette Shawna, Serra Ryan W, Peng Min, Hayes Janelle A, Konstantinopoulos Panagiotis A, Green Michael R, Cantor Sharon B
Abstract excerpt
Hereditary cancers derive from gene defects that often compromise DNA repair. Thus, BRCA-associated cancers are sensitive to DNA-damaging agents such as cisplatin. The efficacy of cisplatin is limited, however, by the development of resistance. One cisplatin resistance mechanism is restoration of homologous recombination (HR), which can result from BRCA reversion mutations. However, in BRCA2 mutant cancers,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.